董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joel Latham | 男 | Chief Executive Officer,Director and President | 36 | 112.77万美元 | 168.68 | 2025-12-18 |
| Troy Valentine | 男 | Chairperson | 51 | 33.05万美元 | 108.43 | 2025-12-18 |
| Peter Widdows | 男 | Independent Director | 59 | 10.72万美元 | 28.19 | 2025-12-18 |
| George Anastassov | 男 | Independent Director | 61 | 13.20万美元 | 76.97 | 2025-12-18 |
| Robert Clark | 男 | Independent Director | 65 | 7.50万美元 | 10.00 | 2025-12-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joel Latham | 男 | Chief Executive Officer,Director and President | 36 | 112.77万美元 | 168.68 | 2025-12-18 |
| Lekhram Changoer | 男 | Chief Technology Officer | 59 | 13.76万美元 | 未持股 | 2025-12-18 |
| Joseph Swan | 男 | Chief Financial Officer,Treasurer and Secretary | 34 | 20.12万美元 | 3.79 | 2025-12-18 |
| Luigi M. Barbato | 男 | Chief Medical Officer | 62 | 49.72万美元 | 3.35 | 2025-12-18 |
董事简历
中英对照 | 中文 | 英文- Joel Latham
-
Joel Latham自2018年7月起担任Incannex的首席执行官兼董事总经理。Latham先生负责公司的商业运营、战略决策以及对Incannex公司所有临床开发资产的监督。在被任命为首席执行官之前，莱瑟姆先生一直是Incannex Healthcare Limited高级领导团队的重要成员，自2016年起担任总经理。在此期间，他在营销和采购多种创收机会及合作伙伴关系方面发挥了重要作用，包括与Pacific Smiles ASX：PSQ、1300 Smiles（ASX：ONT）、美国国家橄榄球联盟、澳大利亚橄榄球联盟、ONE Fighting Championship、FIT Technologies和Cannvalate。在公司任职期间，Latham先生在开发和执行Incannex的药物开发和监管战略方面发挥了关键作用。在2016年加入Incannex之前，Latham先生拥有超过14年的经验，曾在Mars Foods、Tabcorp和Philip Morris International等大型公司担任管理和商业运营职务。
Joel Latham,has served as the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. since July 2023. With over 20 years of experience in both public and private sectors, Mr. Latham leads Incannex's strategic vision, focusing on advancing innovative therapies through clinical development and regulatory approval. Previously, he was the Chief Executive Officer and Managing Director of Incannex Healthcare Limited, which became a subsidiary of Incannex following the re-domiciliation ("Incannex Australia"), where he played a key role in the company's growth and its successful transition to Nasdaq. Prior to his appointment as Chief Executive Officer of Incannex Australia, Mr. Latham was the General Manager of Incannex Australia since 2016. Mr. Latham has also held senior roles at Mars Foods, Tabcorp, and Philip Morris International, bringing extensive expertise in corporate strategy and global market expansion. - Joel Latham自2018年7月起担任Incannex的首席执行官兼董事总经理。Latham先生负责公司的商业运营、战略决策以及对Incannex公司所有临床开发资产的监督。在被任命为首席执行官之前，莱瑟姆先生一直是Incannex Healthcare Limited高级领导团队的重要成员，自2016年起担任总经理。在此期间，他在营销和采购多种创收机会及合作伙伴关系方面发挥了重要作用，包括与Pacific Smiles ASX：PSQ、1300 Smiles（ASX：ONT）、美国国家橄榄球联盟、澳大利亚橄榄球联盟、ONE Fighting Championship、FIT Technologies和Cannvalate。在公司任职期间，Latham先生在开发和执行Incannex的药物开发和监管战略方面发挥了关键作用。在2016年加入Incannex之前，Latham先生拥有超过14年的经验，曾在Mars Foods、Tabcorp和Philip Morris International等大型公司担任管理和商业运营职务。
- Joel Latham,has served as the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. since July 2023. With over 20 years of experience in both public and private sectors, Mr. Latham leads Incannex's strategic vision, focusing on advancing innovative therapies through clinical development and regulatory approval. Previously, he was the Chief Executive Officer and Managing Director of Incannex Healthcare Limited, which became a subsidiary of Incannex following the re-domiciliation ("Incannex Australia"), where he played a key role in the company's growth and its successful transition to Nasdaq. Prior to his appointment as Chief Executive Officer of Incannex Australia, Mr. Latham was the General Manager of Incannex Australia since 2016. Mr. Latham has also held senior roles at Mars Foods, Tabcorp, and Philip Morris International, bringing extensive expertise in corporate strategy and global market expansion.
- Troy Valentine
-
特洛伊·瓦伦丁自2017年12月起担任董事会主席。Valentine先生是一名财务专业人士，拥有超过27年的管理和董事会经验。他的职业生涯始于1994年的澳大利亚经纪公司Hartley Poynton，现为Euroz Hartleys Limited，之后于2000年加入Patersons Securities（现为Canaccord Genuity），随后成为副董事。在Patersons任职期间，他负责管理零售账户和机构账户。瓦伦丁拥有丰富的企业和融资经验，尤其是在初创企业和中小型公司。他目前还是澳大利亚精品企业咨询公司Alignment Capital Pty Ltd的董事，该公司是他于2014年共同创立的。
Troy Valentine,has served as the Chairperson of the Board of Directors of Incannex Healthcare Inc. since November 2023 and was the Chairperson of the Board for Incannex Australia from December 2017 to November 2023. With over 30 years of experience in finance, managerial, and board roles, Mr. Valentine began his career at Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000, where he became an Associate Director. He is also a director and co-founder of Alignment Capital Pty Ltd, a boutique corporate advisory firm established in 2014. Mr. Valentine holds a Bachelor of Commerce from the University of Western Australia. - 特洛伊·瓦伦丁自2017年12月起担任董事会主席。Valentine先生是一名财务专业人士，拥有超过27年的管理和董事会经验。他的职业生涯始于1994年的澳大利亚经纪公司Hartley Poynton，现为Euroz Hartleys Limited，之后于2000年加入Patersons Securities（现为Canaccord Genuity），随后成为副董事。在Patersons任职期间，他负责管理零售账户和机构账户。瓦伦丁拥有丰富的企业和融资经验，尤其是在初创企业和中小型公司。他目前还是澳大利亚精品企业咨询公司Alignment Capital Pty Ltd的董事，该公司是他于2014年共同创立的。
- Troy Valentine,has served as the Chairperson of the Board of Directors of Incannex Healthcare Inc. since November 2023 and was the Chairperson of the Board for Incannex Australia from December 2017 to November 2023. With over 30 years of experience in finance, managerial, and board roles, Mr. Valentine began his career at Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000, where he became an Associate Director. He is also a director and co-founder of Alignment Capital Pty Ltd, a boutique corporate advisory firm established in 2014. Mr. Valentine holds a Bachelor of Commerce from the University of Western Australia.
- Peter Widdows
-
Peter Widdows自2018年起担任董事。他是一名资深特许会计师，在各种业务职能方面拥有丰富的经验。他在澳大利亚和国际消费品市场拥有丰富的经验，曾在欧洲、美国和亚太地区等多个地区担任高级主管。特别是，Widdows先生于2008年至2010年在H. J. Heinz公司担任大洋洲和大中华区区域首席执行官，并于2002年至2008年在H. J. Heinz公司担任澳大利亚首席执行官兼董事总经理并于1998年至2000年在辛辛那提的Starkist Foods Inc.担任战略与规划总经理。自2018年9月以来，Widdows先生一直担任Sunny Queen Australia Ltd的董事长，该公司是澳大利亚最大的带壳鸡蛋和蛋类食品生产商，同时也是澳大利亚普通保险公司Youi Insurance Holdings Ltd的非执行董事。
Peter Widdows,has served as a Director of Incannex Healthcare Inc. since November 2023, following his role as Director at Incannex Australia from March 2018 to November 2023. Mr. Widdows is the current Board Chair and and non-executive director of Youi Insurance, an Australian general Insurance company and the non-executive Chaiman of Sunny Queens Australia, an Australian FMCG company. He has extensive experience in global leadership having served as the Regional Chief Executive Officer for a large part of Asia and Australasia for H. J. Heinz Company, a global food company, from 2008 to 2010, and earlier, the Chief Executive Officer and Managing Director for Heinz Australia from 2002 to 2008. He also held managing director roles in New Zealand and senior Strategic and Finace executive roles at StarKist Foods Inc, a global seafood and petfood company based in Cincinnati, Ohio. He is a Fellow of the Institute of Chartered Accountants in England and Wales. - Peter Widdows自2018年起担任董事。他是一名资深特许会计师，在各种业务职能方面拥有丰富的经验。他在澳大利亚和国际消费品市场拥有丰富的经验，曾在欧洲、美国和亚太地区等多个地区担任高级主管。特别是，Widdows先生于2008年至2010年在H. J. Heinz公司担任大洋洲和大中华区区域首席执行官，并于2002年至2008年在H. J. Heinz公司担任澳大利亚首席执行官兼董事总经理并于1998年至2000年在辛辛那提的Starkist Foods Inc.担任战略与规划总经理。自2018年9月以来，Widdows先生一直担任Sunny Queen Australia Ltd的董事长，该公司是澳大利亚最大的带壳鸡蛋和蛋类食品生产商，同时也是澳大利亚普通保险公司Youi Insurance Holdings Ltd的非执行董事。
- Peter Widdows,has served as a Director of Incannex Healthcare Inc. since November 2023, following his role as Director at Incannex Australia from March 2018 to November 2023. Mr. Widdows is the current Board Chair and and non-executive director of Youi Insurance, an Australian general Insurance company and the non-executive Chaiman of Sunny Queens Australia, an Australian FMCG company. He has extensive experience in global leadership having served as the Regional Chief Executive Officer for a large part of Asia and Australasia for H. J. Heinz Company, a global food company, from 2008 to 2010, and earlier, the Chief Executive Officer and Managing Director for Heinz Australia from 2002 to 2008. He also held managing director roles in New Zealand and senior Strategic and Finace executive roles at StarKist Foods Inc, a global seafood and petfood company based in Cincinnati, Ohio. He is a Fellow of the Institute of Chartered Accountants in England and Wales.
- George Anastassov
-
George Anastassov自2022年6月起担任董事。Anastassov博士在与FDA和EMA联络和谈判方面积累了丰富的经验，因为他多年来向监管机构提交了许多监管文件，包括IND会议包和IND申请。Anastassov博士是世界上第一个含有大麻素的口香糖递送系统的开发者之一。在被任命为董事之前，Anastassov博士自2017年至2022年一直担任APIRx Pharmaceuticals LLC的创始董事总经理，同时也是医学和科学咨询团队的重要成员，协助开发组合化合物。此前，阿纳斯塔索夫博士一直是AXIM Biotechnologies的首席执行官和联合创始人，该公司自2014年至2018年实现了约12亿美元的历史最高市值。
George Anastassov,has been a Director of Incannex Healthcare Inc. since November 2023, following his role as Director at Incannex Australia from June 2022 to November 2023. A pioneer in cannabinoid-based therapeutics, Dr. Anastassov co-developed the world's first cannabinoid-containing chewing gum delivery system. From September, 2000 to July, 2019, he served as the Director of Sannamad Foundation and Sannamad Pharmaceuticals, a Biotechnology Company he cofounded. He co-founded and served as Managing Director of APIRx Pharmaceuticals LLC from 2017 to 2022, playing a pivotal role in the development of Combination Compounds for wide range of medical indications. Previously, he was the CEO and co-founder of AXIM Biotechnologies, an biotechnology research and development company, from 2014 to 2018. Under Dr. Anastassov' leadership AXIM was voted as top 5 growing biotech companies by Fox Business News in 2017. Dr. Anastassov holds a BA degree in Fine Arts from The Fine Arts School in Sofia, Bulgaria, MD degree from Higher Medical Institute, Sofia, Bulgaria, DDS degree from New York University and a MBA degree from Haslam Business School, The University of Tennessee, Knoxville. Dr. Anastassov is trained as a craniomaxillofacial and base of the skull surgeon and has been on the clinical and academic faculty at Mt. Sinai School of Medicine, New York, USA since July of 1997. - George Anastassov自2022年6月起担任董事。Anastassov博士在与FDA和EMA联络和谈判方面积累了丰富的经验，因为他多年来向监管机构提交了许多监管文件，包括IND会议包和IND申请。Anastassov博士是世界上第一个含有大麻素的口香糖递送系统的开发者之一。在被任命为董事之前，Anastassov博士自2017年至2022年一直担任APIRx Pharmaceuticals LLC的创始董事总经理，同时也是医学和科学咨询团队的重要成员，协助开发组合化合物。此前，阿纳斯塔索夫博士一直是AXIM Biotechnologies的首席执行官和联合创始人，该公司自2014年至2018年实现了约12亿美元的历史最高市值。
- George Anastassov,has been a Director of Incannex Healthcare Inc. since November 2023, following his role as Director at Incannex Australia from June 2022 to November 2023. A pioneer in cannabinoid-based therapeutics, Dr. Anastassov co-developed the world's first cannabinoid-containing chewing gum delivery system. From September, 2000 to July, 2019, he served as the Director of Sannamad Foundation and Sannamad Pharmaceuticals, a Biotechnology Company he cofounded. He co-founded and served as Managing Director of APIRx Pharmaceuticals LLC from 2017 to 2022, playing a pivotal role in the development of Combination Compounds for wide range of medical indications. Previously, he was the CEO and co-founder of AXIM Biotechnologies, an biotechnology research and development company, from 2014 to 2018. Under Dr. Anastassov' leadership AXIM was voted as top 5 growing biotech companies by Fox Business News in 2017. Dr. Anastassov holds a BA degree in Fine Arts from The Fine Arts School in Sofia, Bulgaria, MD degree from Higher Medical Institute, Sofia, Bulgaria, DDS degree from New York University and a MBA degree from Haslam Business School, The University of Tennessee, Knoxville. Dr. Anastassov is trained as a craniomaxillofacial and base of the skull surgeon and has been on the clinical and academic faculty at Mt. Sinai School of Medicine, New York, USA since July of 1997.
- Robert Clark
-
Robert Clark自2022年8月起担任董事。克拉克先生是一名高级战略监管事务专家，拥有38年以上的美国和国际监管经验，其中包括在辉瑞公司工作20年以上，在诺和诺德公司工作10年以上，他是FDA和EMA事务方面的专家，美国有关医疗保健专业人员和销售人员活动的药品广告惯例和法规方面的问题。自2012年5月起，Clark先生担任诺和诺德美国监管事务副总裁，在该公司为一支由50多名监管人员和科学家组成的新药开发团队提供战略领导。在被任命为董事之前，Clark先生从1992年至2021年一直担任辉瑞公司全球监管战略和美国监管事务副总裁，领导一支由多达150名区域监管专业人员组成的团队，为药物开发和批准过程提供支持。
Robert Clark,has been a Director of Incannex Healthcare Inc. since November 2023, having previously held the same position at Incannex Australia from August 2022 to November 2023. He is a seasoned expert in strategic regulatory affairs, boasting over 40 years of extensive regulatory experience in the U.S. and internationally. Mr. Clark spent more than 20 years at Pfizer Inc., a pharmaceutical and biotechnology company, and over 10 years at Novo Nordisk. Since May 2012, he has held the role of Vice President, U.S. Regulatory Affairs at Novo Nordisk. Prior to this, he served as Vice President of Worldwide Regulatory Strategy and U.S. Regulatory Affairs at Pfizer from 1992 to 2021. Mr. Clark holds a Masters of Science degree in Pharmacology from New York Medical College. - Robert Clark自2022年8月起担任董事。克拉克先生是一名高级战略监管事务专家，拥有38年以上的美国和国际监管经验，其中包括在辉瑞公司工作20年以上，在诺和诺德公司工作10年以上，他是FDA和EMA事务方面的专家，美国有关医疗保健专业人员和销售人员活动的药品广告惯例和法规方面的问题。自2012年5月起，Clark先生担任诺和诺德美国监管事务副总裁，在该公司为一支由50多名监管人员和科学家组成的新药开发团队提供战略领导。在被任命为董事之前，Clark先生从1992年至2021年一直担任辉瑞公司全球监管战略和美国监管事务副总裁，领导一支由多达150名区域监管专业人员组成的团队，为药物开发和批准过程提供支持。
- Robert Clark,has been a Director of Incannex Healthcare Inc. since November 2023, having previously held the same position at Incannex Australia from August 2022 to November 2023. He is a seasoned expert in strategic regulatory affairs, boasting over 40 years of extensive regulatory experience in the U.S. and internationally. Mr. Clark spent more than 20 years at Pfizer Inc., a pharmaceutical and biotechnology company, and over 10 years at Novo Nordisk. Since May 2012, he has held the role of Vice President, U.S. Regulatory Affairs at Novo Nordisk. Prior to this, he served as Vice President of Worldwide Regulatory Strategy and U.S. Regulatory Affairs at Pfizer from 1992 to 2021. Mr. Clark holds a Masters of Science degree in Pharmacology from New York Medical College.
高管简历
中英对照 | 中文 | 英文- Joel Latham
Joel Latham自2018年7月起担任Incannex的首席执行官兼董事总经理。Latham先生负责公司的商业运营、战略决策以及对Incannex公司所有临床开发资产的监督。在被任命为首席执行官之前，莱瑟姆先生一直是Incannex Healthcare Limited高级领导团队的重要成员，自2016年起担任总经理。在此期间，他在营销和采购多种创收机会及合作伙伴关系方面发挥了重要作用，包括与Pacific Smiles ASX：PSQ、1300 Smiles（ASX：ONT）、美国国家橄榄球联盟、澳大利亚橄榄球联盟、ONE Fighting Championship、FIT Technologies和Cannvalate。在公司任职期间，Latham先生在开发和执行Incannex的药物开发和监管战略方面发挥了关键作用。在2016年加入Incannex之前，Latham先生拥有超过14年的经验，曾在Mars Foods、Tabcorp和Philip Morris International等大型公司担任管理和商业运营职务。
Joel Latham,has served as the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. since July 2023. With over 20 years of experience in both public and private sectors, Mr. Latham leads Incannex's strategic vision, focusing on advancing innovative therapies through clinical development and regulatory approval. Previously, he was the Chief Executive Officer and Managing Director of Incannex Healthcare Limited, which became a subsidiary of Incannex following the re-domiciliation ("Incannex Australia"), where he played a key role in the company's growth and its successful transition to Nasdaq. Prior to his appointment as Chief Executive Officer of Incannex Australia, Mr. Latham was the General Manager of Incannex Australia since 2016. Mr. Latham has also held senior roles at Mars Foods, Tabcorp, and Philip Morris International, bringing extensive expertise in corporate strategy and global market expansion.- Joel Latham自2018年7月起担任Incannex的首席执行官兼董事总经理。Latham先生负责公司的商业运营、战略决策以及对Incannex公司所有临床开发资产的监督。在被任命为首席执行官之前，莱瑟姆先生一直是Incannex Healthcare Limited高级领导团队的重要成员，自2016年起担任总经理。在此期间，他在营销和采购多种创收机会及合作伙伴关系方面发挥了重要作用，包括与Pacific Smiles ASX：PSQ、1300 Smiles（ASX：ONT）、美国国家橄榄球联盟、澳大利亚橄榄球联盟、ONE Fighting Championship、FIT Technologies和Cannvalate。在公司任职期间，Latham先生在开发和执行Incannex的药物开发和监管战略方面发挥了关键作用。在2016年加入Incannex之前，Latham先生拥有超过14年的经验，曾在Mars Foods、Tabcorp和Philip Morris International等大型公司担任管理和商业运营职务。
- Joel Latham,has served as the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. since July 2023. With over 20 years of experience in both public and private sectors, Mr. Latham leads Incannex's strategic vision, focusing on advancing innovative therapies through clinical development and regulatory approval. Previously, he was the Chief Executive Officer and Managing Director of Incannex Healthcare Limited, which became a subsidiary of Incannex following the re-domiciliation ("Incannex Australia"), where he played a key role in the company's growth and its successful transition to Nasdaq. Prior to his appointment as Chief Executive Officer of Incannex Australia, Mr. Latham was the General Manager of Incannex Australia since 2016. Mr. Latham has also held senior roles at Mars Foods, Tabcorp, and Philip Morris International, bringing extensive expertise in corporate strategy and global market expansion.
- Lekhram Changoer
Lekhram Changoer自2022年6月起担任Incannex的首席技术官。他负责制定和实施用于临床和商业制造药物疗法的科学和技术战略。在加入Incannex公司之前，Changoer先生是APIRx公司的董事。在此之前，Changoer先生自2014年至2018年担任AXIM Biotechnologies的CTO和联合创始人。
Lekhram Changoer,has served as the Chief Technology Officer of Incannex Healthcare Inc. since July 2023, where he oversees Incannex Healthcare Inc.'s technology strategy and innovation initiatives. Prior to this, he was the Chief Technology Officer of Incannex Australia from June 2022 to November 2023, following the acquisition of APIRx Pharmaceuticals LLC, a company he co-founded. At APIRx Pharmaceuticals, Mr. Changoer served as the Chief Technology Officer and Director from January 2019 to June 2023, specializing in cannabinoid-based active pharmaceutical ingredients. Before APIRx, he co-founded also other pharmaceutical R&D companies e.g. AXIM Biotechnologies, a pharmaceutical R&D company, and served as its Chief Technology Officer from October 2014 to May 2020. Mr. Changoer holds a MSc and BSc Degree from the University of Groningen (NL) and Rijkshogeschool Groningen (NL).- Lekhram Changoer自2022年6月起担任Incannex的首席技术官。他负责制定和实施用于临床和商业制造药物疗法的科学和技术战略。在加入Incannex公司之前，Changoer先生是APIRx公司的董事。在此之前，Changoer先生自2014年至2018年担任AXIM Biotechnologies的CTO和联合创始人。
- Lekhram Changoer,has served as the Chief Technology Officer of Incannex Healthcare Inc. since July 2023, where he oversees Incannex Healthcare Inc.'s technology strategy and innovation initiatives. Prior to this, he was the Chief Technology Officer of Incannex Australia from June 2022 to November 2023, following the acquisition of APIRx Pharmaceuticals LLC, a company he co-founded. At APIRx Pharmaceuticals, Mr. Changoer served as the Chief Technology Officer and Director from January 2019 to June 2023, specializing in cannabinoid-based active pharmaceutical ingredients. Before APIRx, he co-founded also other pharmaceutical R&D companies e.g. AXIM Biotechnologies, a pharmaceutical R&D company, and served as its Chief Technology Officer from October 2014 to May 2020. Mr. Changoer holds a MSc and BSc Degree from the University of Groningen (NL) and Rijkshogeschool Groningen (NL).
- Joseph Swan
Joseph Swan，自2024年2月起担任Incannex Healthcare公司的首席财务官兼秘书，负责监督公司的财务战略、报告和监管合规。此前，他曾于2023年7月至2024年2月担任公司财务主管和财务总监，在此之前，他曾于2021年11月至2023年11月担任Incannex Australia的财务主管。在加入Incannex之前，Joseph曾在澳大利亚会计和咨询公司HLB Mann Judd担任审计主管，在INPEX Australia担任内部审计师，在Deloitte Australia担任分析师。他是一名特许会计师，拥有西澳大利亚大学会计学专业的商业学位。
Joseph Swan,has served as the Chief Financial Officer and Secretary of Incannex Healthcare Inc. since February 2024, where he oversees the company's financial strategy, reporting, and regulatory compliance. Previously, he was Incannex Healthcare Inc.'s Treasurer and Controller from July 2023 to February 2024, and before that, he served as Head of Finance for Incannex Australia from November 2021 to November 2023. Prior to joining Incannex Healthcare Inc., Joseph held roles as an Audit Supervisor at HLB Mann Judd, an Australian accounting and advisory firm, from May 2020 to November 2021, an internal auditor at INPEX Australia, an energy company, from July 2017 to July 2018, and an analyst at Deloitte Australia, an accounting firm, from February 2015 to June 2017. He is a chartered accountant and holds a degree in commerce, majoring in accounting, from the University of Western Australia.- Joseph Swan，自2024年2月起担任Incannex Healthcare公司的首席财务官兼秘书，负责监督公司的财务战略、报告和监管合规。此前，他曾于2023年7月至2024年2月担任公司财务主管和财务总监，在此之前，他曾于2021年11月至2023年11月担任Incannex Australia的财务主管。在加入Incannex之前，Joseph曾在澳大利亚会计和咨询公司HLB Mann Judd担任审计主管，在INPEX Australia担任内部审计师，在Deloitte Australia担任分析师。他是一名特许会计师，拥有西澳大利亚大学会计学专业的商业学位。
- Joseph Swan,has served as the Chief Financial Officer and Secretary of Incannex Healthcare Inc. since February 2024, where he oversees the company's financial strategy, reporting, and regulatory compliance. Previously, he was Incannex Healthcare Inc.'s Treasurer and Controller from July 2023 to February 2024, and before that, he served as Head of Finance for Incannex Australia from November 2021 to November 2023. Prior to joining Incannex Healthcare Inc., Joseph held roles as an Audit Supervisor at HLB Mann Judd, an Australian accounting and advisory firm, from May 2020 to November 2021, an internal auditor at INPEX Australia, an energy company, from July 2017 to July 2018, and an analyst at Deloitte Australia, an accounting firm, from February 2015 to June 2017. He is a chartered accountant and holds a degree in commerce, majoring in accounting, from the University of Western Australia.
- Luigi M. Barbato
Luigi M. Barbato，自2024年10月起担任Incannex Healthcare公司的首席医疗官，负责监督Incannex Healthcare公司的药物开发项目。在加入Incannex Healthcare公司之前，Barbato博士于2023年5月至2024年10月在爵士制药担任多个针对神经系统疾病的临床阶段治疗项目的全球医疗主管。在加入Jazz之前，Barbato博士于2015年7月至2023年5月期间担任艾伯维全球高级医疗总监。在为艾伯维服务之前，他曾在渤健 Idec、诺华、Stiefel Laboratories（GSK）、Forest Research Institute和Solvay Pharmaceuticals担任领导职务。巴巴托博士曾担任埃默里大学医学院精神病学和行为科学的临床助理教授，撰写或合著了超过65篇论文和演讲。巴巴托博士在圣乔治大学医学院获得医学博士学位，在圣彼得大学获得生物学学士学位。
Luigi M. Barbato,has served as the Chief Medical Officer of Incannex Healthcare Inc. since October 2024, where he oversees Incannex Healthcare Inc.'s drug development programs. Prior to joining Incannex Healthcare Inc., Dr. Barbato served as Global Medical Lead for several clinical-stage therapeutic programs addressing neurological disorders at Jazz Pharmaceuticals from May 2023 until October 2024. Prior to joining Jazz, Dr. Barbato served as Global Senior Medical Director at AbbVie from July 2015 until May 2023, and, prior to his service with AbbVie, he held leadership roles at Biogen Idec, Novartis, Stiefel Laboratories (GSK), Forest Research Institute, and Solvay Pharmaceuticals. Dr. Barbato served as a Clinical Assistant Professor of Psychiatry and Behavioral Science at Emory University School of Medicine, and has authored or co-authored more than 65 papers and presentations. Dr. Barbato earned his M.D. from St. George's University School of Medicine and B.S. in Biology at St. Peter's University.- Luigi M. Barbato，自2024年10月起担任Incannex Healthcare公司的首席医疗官，负责监督Incannex Healthcare公司的药物开发项目。在加入Incannex Healthcare公司之前，Barbato博士于2023年5月至2024年10月在爵士制药担任多个针对神经系统疾病的临床阶段治疗项目的全球医疗主管。在加入Jazz之前，Barbato博士于2015年7月至2023年5月期间担任艾伯维全球高级医疗总监。在为艾伯维服务之前，他曾在渤健 Idec、诺华、Stiefel Laboratories（GSK）、Forest Research Institute和Solvay Pharmaceuticals担任领导职务。巴巴托博士曾担任埃默里大学医学院精神病学和行为科学的临床助理教授，撰写或合著了超过65篇论文和演讲。巴巴托博士在圣乔治大学医学院获得医学博士学位，在圣彼得大学获得生物学学士学位。
- Luigi M. Barbato,has served as the Chief Medical Officer of Incannex Healthcare Inc. since October 2024, where he oversees Incannex Healthcare Inc.'s drug development programs. Prior to joining Incannex Healthcare Inc., Dr. Barbato served as Global Medical Lead for several clinical-stage therapeutic programs addressing neurological disorders at Jazz Pharmaceuticals from May 2023 until October 2024. Prior to joining Jazz, Dr. Barbato served as Global Senior Medical Director at AbbVie from July 2015 until May 2023, and, prior to his service with AbbVie, he held leadership roles at Biogen Idec, Novartis, Stiefel Laboratories (GSK), Forest Research Institute, and Solvay Pharmaceuticals. Dr. Barbato served as a Clinical Assistant Professor of Psychiatry and Behavioral Science at Emory University School of Medicine, and has authored or co-authored more than 65 papers and presentations. Dr. Barbato earned his M.D. from St. George's University School of Medicine and B.S. in Biology at St. Peter's University.